申请人:TAISHO PHARMACEUTICAL CO., LTD
公开号:EP1295865A1
公开(公告)日:2003-03-26
The present invention relates to 2-amino-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivatives represented by the formula:
the pharmaceutically acceptable salts thereof, or the hydrates thereof. The compounds of the present invention are useful as a medicament, and in particular, are useful as modulators acting on group 2 metabotropic glutamate receptors, having effects for treating and/or preventing psychiatric disorders such as schizophrenia, anxiety and its associated diseases, depression, bipolar disorder, and epilepsy; and/or neurological diseases such as drug dependence, cognitive disorders, Alzheimer's disease, Huntington's chorea, Parkinson's disease, dyskinesia associated with muscular stiffness, cerebral ischemia, cerebral failure, myelopathy, and head trauma.
本发明涉及式 2-氨基-6-氟双环[3.1.0]己烷-2,6-二甲酸衍生物:
其药学上可接受的盐或其水合物。本发明的化合物可用作药物,特别是可用作作用于第 2 组代谢谷氨酸受体的调节剂,具有治疗和/或预防精神疾病如精神分裂症、焦虑症及其相关疾病、抑郁症、双相情感障碍和癫痫的作用;和/或神经系统疾病,如药物依赖、认知障碍、阿尔茨海默病、亨廷顿舞蹈症、帕金森病、与肌肉僵硬相关的运动障碍、脑缺血、脑衰竭、脊髓病和头部创伤。